FDA grants priority review to inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer

Inavolisib’s priority review status is based on positive data from a Phase 3 study showing that inavolisib-based regimens significantly extended progression-free survival in patients with hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutations.